$0.58 EPS Expected for LivaNova PLC (NASDAQ:LIVN) This Quarter

Equities analysts expect LivaNova PLC (NASDAQ:LIVNGet Rating) to announce $0.58 earnings per share for the current quarter, according to Zacks. Three analysts have made estimates for LivaNova’s earnings. The highest EPS estimate is $0.63 and the lowest is $0.51. LivaNova reported earnings per share of $0.52 in the same quarter last year, which would indicate a positive year-over-year growth rate of 11.5%. The company is scheduled to issue its next quarterly earnings results on Monday, January 1st.

According to Zacks, analysts expect that LivaNova will report full-year earnings of $2.60 per share for the current fiscal year, with EPS estimates ranging from $2.57 to $2.61. For the next fiscal year, analysts anticipate that the firm will post earnings of $3.05 per share, with EPS estimates ranging from $2.88 to $3.25. Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side research firms that that provide coverage for LivaNova.

LivaNova (NASDAQ:LIVNGet Rating) last issued its quarterly earnings results on Wednesday, May 4th. The company reported $0.48 EPS for the quarter, hitting analysts’ consensus estimates of $0.48. The firm had revenue of $240.20 million for the quarter, compared to analyst estimates of $231.57 million. LivaNova had a negative net margin of 9.69% and a positive return on equity of 9.57%. The business’s revenue for the quarter was down 3.0% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.35 EPS.

A number of equities research analysts have recently issued reports on LIVN shares. Zacks Investment Research cut shares of LivaNova from a “hold” rating to a “sell” rating in a research note on Saturday, February 26th. Needham & Company LLC cut their price objective on shares of LivaNova from $120.00 to $106.00 and set a “buy” rating for the company in a research note on Thursday, February 24th. StockNews.com started coverage on shares of LivaNova in a research note on Thursday, March 31st. They issued a “hold” rating for the company. Wolfe Research started coverage on shares of LivaNova in a research note on Tuesday, April 5th. They issued an “outperform” rating and a $95.00 price objective for the company. Finally, UBS Group raised shares of LivaNova from a “neutral” rating to a “buy” rating and set a $96.00 price objective for the company in a research note on Thursday, February 24th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have issued a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $100.71.

In other news, CEO Damien Mcdonald sold 2,784 shares of the firm’s stock in a transaction dated Tuesday, March 29th. The shares were sold at an average price of $81.50, for a total transaction of $226,896.00. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Daniel Jeffrey Moore sold 1,000 shares of the firm’s stock in a transaction dated Friday, April 1st. The shares were sold at an average price of $83.42, for a total transaction of $83,420.00. Following the sale, the director now directly owns 24,630 shares in the company, valued at approximately $2,054,634.60. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 5,784 shares of company stock valued at $470,316. Corporate insiders own 0.37% of the company’s stock.

Several hedge funds and other institutional investors have recently made changes to their positions in LIVN. Henry James International Management Inc. boosted its holdings in shares of LivaNova by 1.0% in the fourth quarter. Henry James International Management Inc. now owns 14,417 shares of the company’s stock worth $1,260,000 after buying an additional 141 shares during the last quarter. Amalgamated Bank boosted its holdings in shares of LivaNova by 0.5% in the fourth quarter. Amalgamated Bank now owns 37,437 shares of the company’s stock worth $3,273,000 after buying an additional 173 shares during the last quarter. Column Capital Advisors LLC boosted its holdings in shares of LivaNova by 109.1% in the first quarter. Column Capital Advisors LLC now owns 345 shares of the company’s stock worth $28,000 after buying an additional 180 shares during the last quarter. Louisiana State Employees Retirement System boosted its holdings in shares of LivaNova by 1.5% in the first quarter. Louisiana State Employees Retirement System now owns 13,900 shares of the company’s stock worth $1,204,000 after buying an additional 200 shares during the last quarter. Finally, US Bancorp DE boosted its holdings in shares of LivaNova by 15.3% in the third quarter. US Bancorp DE now owns 1,564 shares of the company’s stock worth $123,000 after buying an additional 208 shares during the last quarter. 97.34% of the stock is currently owned by hedge funds and other institutional investors.

Shares of NASDAQ:LIVN opened at $65.50 on Friday. The company’s fifty day moving average price is $78.93 and its 200-day moving average price is $80.49. The firm has a market capitalization of $3.50 billion, a price-to-earnings ratio of -32.91 and a beta of 0.91. LivaNova has a one year low of $63.36 and a one year high of $93.89. The company has a debt-to-equity ratio of 0.35, a current ratio of 2.63 and a quick ratio of 0.82.

LivaNova Company Profile (Get Rating)

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates through three segments: Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.

Featured Stories

Get a free copy of the Zacks research report on LivaNova (LIVN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for LivaNova (NASDAQ:LIVN)

Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.